LONG-TERM COST-EFFECTIVENESS OF IGLARLIXI VERSUS IDEGLIRA IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES TREATED WITH BASAL INSULIN OR ORAL ANTIDIABETIC DRUG IN CHINA

被引：0
|
作者：
Mo, X. [1 ]
Ai, Y. [2 ]
Tan, J. [3 ]
Wang, L. J. [3 ]
机构：
[1] IQVIA China, Real World Solut, Shanghai 31, Peoples R China
[2] IQVIA China, Real World Solut, Shanghai, Peoples R China
[3] Sanofi, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE107
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [21] LONG-TERM COST UTILITY ANALYSIS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION THERAPIES IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN IN SPAIN
    Prades, M.
    Lizan, L.
    Hunt, B.
    Ramirez de Arellano, A.
    VALUE IN HEALTH, 2016, 19 (03) : A99 - A99
  • [22] Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents
    Valentine, William J.
    Palmer, Andrew J.
    Lammert, Morten
    Langer, Jakob
    Braendle, Michael
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1698 - 1712
  • [23] Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
    Melanie J. Davies
    Divina Glah
    Barrie Chubb
    Gerasimos Konidaris
    Phil McEwan
    PharmacoEconomics, 2016, 34 : 953 - 966
  • [24] Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
    Davies, Melanie J.
    Glah, Divina
    Chubb, Barrie
    Konidaris, Gerasimos
    McEwan, Phil
    PHARMACOECONOMICS, 2016, 34 (09) : 953 - 966
  • [25] LONG-TERM COST EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS GLP-1 ADDED TO BASAL INSULIN AS INTENSIFICATION THERAPIES IN TYPE 2 DIABETES MELLITUS IN SPAIN
    Prades, M.
    Lizan, L.
    Hunt, B.
    Ramirez de Arellano, A.
    VALUE IN HEALTH, 2016, 19 (03) : A99 - A99
  • [26] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Hui Shao
    Abdul Jabbar Omar Alsaleh
    Terry Dex
    Elisheva Lew
    Vivian Fonseca
    Diabetes Therapy, 2022, 13 : 1659 - 1670
  • [27] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Shao, Hui
    Alsaleh, Abdul Jabbar Omar
    Dex, Terry
    Lew, Elisheva
    Fonseca, Vivian
    DIABETES THERAPY, 2022, 13 (09) : 1659 - 1670
  • [28] Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
    McCrimmon, Rory J.
    Lamotte, Mark
    Ramos, Mafalda
    Alsaleh, Abdul Jabbar Omar
    Souhami, Elisabeth
    Lew, Elisheva
    DIABETES THERAPY, 2021, 12 (12) : 3231 - 3241
  • [29] Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
    Rory J. McCrimmon
    Mark Lamotte
    Mafalda Ramos
    Abdul Jabbar Omar Alsaleh
    Elisabeth Souhami
    Elisheva Lew
    Diabetes Therapy, 2021, 12 : 3231 - 3241
  • [30] Star.ro - real world data on effectiveness and safety of iglarlixi in people with type 2 diabetes uncontrolled on oral antidiabetic drugs ± basal insulin treatment
    Guja, C.
    Bala, C.
    Cerghizan, A.
    Mihai, B.
    Moise, M.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 268 - 269
12345